Initiation of Anti-Cholesterol Drugs in Patients with Cardiovascular Disease

Secondary Prevention

The American College of Cardiology recommends high-intensity statin therapy for all patients ≤75 years with clinical atherosclerotic cardiovascular disease (ASCVD), including those with myocardial infarction, stable or unstable angina, coronary revascularization, stroke, TIA, or peripheral arterial disease 1, 2
The European Society of Cardiology suggests initiating or continuing high-dose statins early after admission in all acute coronary syndrome patients, regardless of baseline LDL-cholesterol values 3, 4, 5, 6
For patients >75 years with established ASCVD, the American College of Cardiology recommends using moderate-intensity statins as first-line, though high-intensity therapy remains reasonable if tolerated 1, 2
Moderate-intensity statins are the alternative for younger patients with contraindications or intolerance to high-intensity regimens, according to the American College of Cardiology 1

The European Society of Cardiology recommends LDL-cholesterol lowering of at least 50% with statins in patients with type 1 diabetes and microalbuminuria or renal disease, irrespective of baseline LDL-cholesterol 4, 5
Patients with type 2 diabetes and cardiovascular disease, chronic kidney disease, or age >40 years with additional risk factors should receive statin therapy targeting LDL-cholesterol <1.8 mmol/L (<70 mg/dL), as suggested by the European Society of Cardiology 4, 5
Stage 3-5 chronic kidney disease (non-dialysis) requires statins or statin/ezetimibe combination, as these patients are at high or very high cardiovascular risk, according to the European Society of Cardiology 3, 4, 5, 6
Peripheral arterial disease or carotid artery disease is a very high-risk condition requiring statin therapy, as recommended by the European Society of Cardiology 3, 4, 5, 6

Dialysis-dependent CKD patients without atherosclerotic CVD should not initiate statins, as evidence does not support benefit in this population, according to the European Society of Cardiology 3, 4, 5, 6

Heart failure without other indications: Cholesterol-lowering therapy with statins is not recommended (though not harmful) in patients with heart failure absent other indications, as stated by the European Society of Cardiology 3, 4, 5, 6
Aortic valvular stenosis without coronary artery disease: Cholesterol-lowering treatment is not recommended absent other indications, according to the European Society of Cardiology 3, 4, 5, 6
Autoimmune diseases: Universal use of lipid-lowering drugs is not recommended, as suggested by the European Society of Cardiology 3, 4, 5, 6

Assess LDL-cholesterol response 4-12 weeks after initiating therapy, evaluating percentage reduction rather than absolute values, as recommended by Praxis Medical Insights 7
If target 50% reduction is not achieved with maximum tolerated statin, add ezetimibe as next step, according to Praxis Medical Insights 7

The American College of Cardiology and American Heart Association recommend that high-intensity statin therapy should be continued for life in all patients with established atherosclerotic cardiovascular disease, including those with acute coronary syndromes, myocardial infarction, stable or unstable angina, coronary revascularization, stroke, TIA, or peripheral arterial disease 8, 9, 10.
The European Society of Cardiology recommends statins in all patients with chronic coronary syndromes, emphasizing that this is continuous, not time-limited therapy 9.

Long-term follow-up of statin trials demonstrates persistently reduced cardiovascular risk in statin-treated patients over the next decade or two after trial completion, demonstrating a "legacy effect" of plaque stabilization 11.
The benefit of high-intensity statins after acute coronary syndromes appears early and persists over time, with no indication that this benefit diminishes with continued use 8.
The addition of ezetimibe to statin therapy showed modest but significant MACE reduction over a median follow-up of 6 years, and PCSK9 inhibitor trials demonstrated benefit over 2-3 years, suggesting that lipid-lowering benefits accumulate over extended periods 8.

The American College of Cardiology recommends that statin therapy should be initiated within 24 hours of hospitalization for acute coronary syndromes and continued indefinitely thereafter 8, 12.
Early initiation (within the first 24 hours after ACS onset) is recommended for all patients presenting with any form of ACS unless strictly contraindicated 12.

The American College of Cardiology recommends high-intensity statin regimens (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for patients ≤75 years with clinical ASCVD to achieve ≥50% LDL-C reduction 8.
If maximum-tolerated statin intensity does not achieve desired LDL-C targets, add nonstatin therapy (ezetimibe, PCSK9 inhibitors, or bempedoic acid) rather than discontinuing the statin 8, 9.

The American College of Cardiology recommends never discontinuing statins during hospitalization or follow-up based on achieving LDL-C goals, as the benefit is related to the intensity of therapy maintained over time, not to reaching a specific number 8, 10, 13.
Avoid the misconception that statins are only needed for a fixed duration (e.g., "5 years after MI")—atherosclerosis is a chronic, progressive disease requiring continuous treatment 10, 9.

The American College of Cardiology recommends statins for patients with established atherosclerotic disease, as they reduce cardiovascular events by approximately 21% per 1-mmol/L LDL-C reduction, with consistent benefits observed across all baseline LDL-cholesterol levels 14
The American College of Cardiology suggests that high-intensity statin therapy produces an additional 15% reduction in major vascular events compared to moderate-intensity therapy, independent of the absolute LDL-cholesterol achieved 15

The American Heart Association notes that statins demonstrate specific cerebrovascular protective effects, with atorvastatin 80 mg reducing stroke recurrence by 16% in patients with recent stroke or TIA, even in those without coronary heart disease 16
The European Society of Cardiology recommends statin pre-treatment to lower recurrent stroke risk following transient ischemic attack 17
The International Stroke Society suggests that statin benefits occur regardless of baseline cholesterol levels, indicating mechanisms beyond lipid lowering 18, 16

The European Society of Cardiology notes that statins significantly improve pain-free walking distance and walking time in patients with intermittent claudication 17
The European Society of Cardiology recommends combining statins with aggressive LDL-lowering strategies to reduce major adverse limb events (MALE) 17

The American College of Cardiology recommends initiating high-intensity statin therapy in all patients ≤75 years with established atherosclerotic cardiovascular disease, regardless of baseline LDL-cholesterol 15
The American College of Cardiology suggests avoiding the misconception that statins are only needed when cholesterol is elevated, as patients with atherosclerotic disease benefit even with normal baseline lipid levels 18, 17